



# Bevacizumab Solution for Intravenous Infusion

## FMEC Responses to Questions from the Drug Programs

### Response Summary

Implementation Issues	FMEC Response
<b>Considerations for Discontinuation of Therapy</b>	
Is there evidence to support continuing treatment with single agent bevacizumab if patient is unable to tolerate bevacizumab-lomustine?  What is the rationale (if any) to continue on bevacizumab, if lomustine is discontinued?	FMEC refers to the discontinuation criteria outlined in Table 2 of the reimbursement recommendation.